期刊
PEPTIDE SCIENCE
卷 115, 期 1, 页码 -出版社
WILEY
DOI: 10.1002/pep2.24289
关键词
beta-amyloid; Alzheimer's disease; immunotherapy; peptide vaccine; tau
In this review, the development of A β and tau peptide vaccines and immunotherapies with monoclonal antibodies in clinical trials against AD is explored. The revival and expedited review of promising monoclonal antibody immunotherapies targeting A β has attracted significant attention.
Peptide vaccines and immunotherapies against aggregating proteins involved in the pathogenesis and progression of Alzheimer's disease (AD)-the beta-amyloid peptide (A beta) and tau-are promising therapeutic avenues against AD. Two decades of effort has led to the controversial United States Food and Drug Administration (FDA) approval of the monoclonal antibody Aducanumab (Aduhelm), which has subsequentially sparked the revival and expedited review of promising monoclonal antibody immunotherapies that target A beta. In this review, we explore the development of A beta and tau peptide vaccines and immunotherapies with monoclonal antibodies in clinical trials against AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据